Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569222975> ?p ?o ?g. }
- W2569222975 abstract "Abstract Abstract 1606 Introduction. Diffuse Large B-cell Lymphoma (DLBCL) patients at high-risk (age-adjusted International Prognostic Index (aa-IPI) 2–3), had a dismal prognosis if treated with conventional chemotherapy. The introduction of intensive regimens and the addition of monoclonal antibody anti-CD20, improved prognosis, but some issues remain unresolved such as: the risk of central nervous system (CNS) relapses and the incidence of late toxicities. We analyzed a series of young DLBCL patients at high-risk consecutively treated in four prospective trials by the Italian Lymphoma Foundation (FIL) with the aim to assess the risk of CNS relapses and late toxicities in this series of patients with a prolonged follow-up Methods. From 1986 to 2006, 278 patients with DLBCL with aa-IPI 2–3 at diagnosis, were enrolled in four consecutive trials previously reported. Thirty-two into a phase II study, treated with 12 weekly infusion of MACOP-B; 39 into a phase II trial with eight weekly MACOP-B infusions followed by high-dose cytarabine, mitoxantrone and dexamethasone (MAD) plus standard BEAM and autologous stem cell transplantation (ASCT); 95 in a phase III trial that randomized high-dose sequential (HDS) chemotherapy plus ASCT (45 patients) vs six courses of dose-dense intensified CHOP (iCHOP) (50 patients); 112 into a phase II trial with four courses of iCHOP in combination with Rituximab followed by Rituximab-MAD + BEAM and ASCT. CNS prophylaxis was not mandatory in the four protocols. Updated data regarding of survival, CNS relapses and late toxicities were recorded on June 2011. Results. Clinical characteristics were: aa-IPI 2 in 55%, aa-IPI 3 in 45%, PS > 2 in 66%, LDH upper normal value in 89%, number of extranodal sites > 2 in 35%, bone marrow involvement in 27% of patients, with no statistical differences between the four trials. With a median follow-up of five years, 5-year Overall Survival (OS) was 63% (95% CI: 57–69%) in the whole series; 5-year OS by treatment was 41% (95%CI: 24–74%) in MACOPB, 54% (95%CI: 37–68%) in MACOPB+MAD+BEAM and ASCT; 53% (95%CI: 38–67%) in HDS+ASCT; 58% (95%CI: 43–70%) in iCHOP; 79% (95%CI: 70–86%) in R-iCHOP+R-MAD+BEAM and ASCT. In a multivariate analysis, the risk of death was significantly reduced in R-iCHOP+R-MAD+BEAM and ASCT (p<.001) and was adversely influenced by age with a progressive increase of five years at diagnosis (p.008) or aa-IPI3 (p.001). Four patients experienced CNS relapses, three of them in R-iCHOP+R-MAD+BEAM and ASCT and one in MACOPB. Only one of the four patients received CNS prophylaxis with intrathecal Methotrexate, even if all of them were at risk for CNS relapse according to Italian Society of Hematology guidelines (Barosi, Hematol 2006). Cumulative incidence of CNS recurrence at 10 years for R-iCHOP+R-MAD+BEAM and ASCT regimen was 3.6% (0 to 7.8). Most frequent late toxicities were dyslipidemia and secondary amenorrhea. Regarding to secondary malignancies, myelodisplasia or acute myeloid leukemia were recorded in three patients, two of them treated with R-iCHOP+R-MAD+BEAM and ASCT, at a median time of seven years off therapy. The actuarial risk of secondary malignancies at 10 years for R-iCHOP+R-MAD+BEAM and ASCT was 4.2% (0 to 10). Conclusions. The addition of Rituximab to dose-dense iCHOP plus high-dose chemotherapy plus BEAM and ASCT improved the outcome in young untreated DLBCL patients at poor prognosis, with an acceptable risk of secondary malignancies and late toxicities. A careful identification of patients at risk could avoid the risk of CNS relapse. Disclosures: Vitolo: Roche Italy: Speakers Bureau; Celgene: Speakers Bureau; Jannsen-Cilag: Speakers Bureau." @default.
- W2569222975 created "2017-01-13" @default.
- W2569222975 creator A5000403848 @default.
- W2569222975 creator A5014255803 @default.
- W2569222975 creator A5015825420 @default.
- W2569222975 creator A5016751546 @default.
- W2569222975 creator A5016803459 @default.
- W2569222975 creator A5020789491 @default.
- W2569222975 creator A5020978640 @default.
- W2569222975 creator A5028704362 @default.
- W2569222975 creator A5036210918 @default.
- W2569222975 creator A5036765926 @default.
- W2569222975 creator A5038898384 @default.
- W2569222975 creator A5039029593 @default.
- W2569222975 creator A5042719564 @default.
- W2569222975 creator A5042850515 @default.
- W2569222975 creator A5044007749 @default.
- W2569222975 creator A5064302985 @default.
- W2569222975 creator A5065443409 @default.
- W2569222975 creator A5069053301 @default.
- W2569222975 creator A5071466957 @default.
- W2569222975 creator A5071803772 @default.
- W2569222975 creator A5079479857 @default.
- W2569222975 date "2011-11-18" @default.
- W2569222975 modified "2023-09-27" @default.
- W2569222975 title "Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis" @default.
- W2569222975 doi "https://doi.org/10.1182/blood.v118.21.1606.1606" @default.
- W2569222975 hasPublicationYear "2011" @default.
- W2569222975 type Work @default.
- W2569222975 sameAs 2569222975 @default.
- W2569222975 citedByCount "0" @default.
- W2569222975 crossrefType "journal-article" @default.
- W2569222975 hasAuthorship W2569222975A5000403848 @default.
- W2569222975 hasAuthorship W2569222975A5014255803 @default.
- W2569222975 hasAuthorship W2569222975A5015825420 @default.
- W2569222975 hasAuthorship W2569222975A5016751546 @default.
- W2569222975 hasAuthorship W2569222975A5016803459 @default.
- W2569222975 hasAuthorship W2569222975A5020789491 @default.
- W2569222975 hasAuthorship W2569222975A5020978640 @default.
- W2569222975 hasAuthorship W2569222975A5028704362 @default.
- W2569222975 hasAuthorship W2569222975A5036210918 @default.
- W2569222975 hasAuthorship W2569222975A5036765926 @default.
- W2569222975 hasAuthorship W2569222975A5038898384 @default.
- W2569222975 hasAuthorship W2569222975A5039029593 @default.
- W2569222975 hasAuthorship W2569222975A5042719564 @default.
- W2569222975 hasAuthorship W2569222975A5042850515 @default.
- W2569222975 hasAuthorship W2569222975A5044007749 @default.
- W2569222975 hasAuthorship W2569222975A5064302985 @default.
- W2569222975 hasAuthorship W2569222975A5065443409 @default.
- W2569222975 hasAuthorship W2569222975A5069053301 @default.
- W2569222975 hasAuthorship W2569222975A5071466957 @default.
- W2569222975 hasAuthorship W2569222975A5071803772 @default.
- W2569222975 hasAuthorship W2569222975A5079479857 @default.
- W2569222975 hasConcept C126322002 @default.
- W2569222975 hasConcept C141071460 @default.
- W2569222975 hasConcept C143998085 @default.
- W2569222975 hasConcept C2776694085 @default.
- W2569222975 hasConcept C2778041864 @default.
- W2569222975 hasConcept C2778336483 @default.
- W2569222975 hasConcept C2778476033 @default.
- W2569222975 hasConcept C2778559949 @default.
- W2569222975 hasConcept C2779050716 @default.
- W2569222975 hasConcept C2779338263 @default.
- W2569222975 hasConcept C2780653079 @default.
- W2569222975 hasConcept C2780923524 @default.
- W2569222975 hasConcept C2911091166 @default.
- W2569222975 hasConcept C71924100 @default.
- W2569222975 hasConcept C90924648 @default.
- W2569222975 hasConceptScore W2569222975C126322002 @default.
- W2569222975 hasConceptScore W2569222975C141071460 @default.
- W2569222975 hasConceptScore W2569222975C143998085 @default.
- W2569222975 hasConceptScore W2569222975C2776694085 @default.
- W2569222975 hasConceptScore W2569222975C2778041864 @default.
- W2569222975 hasConceptScore W2569222975C2778336483 @default.
- W2569222975 hasConceptScore W2569222975C2778476033 @default.
- W2569222975 hasConceptScore W2569222975C2778559949 @default.
- W2569222975 hasConceptScore W2569222975C2779050716 @default.
- W2569222975 hasConceptScore W2569222975C2779338263 @default.
- W2569222975 hasConceptScore W2569222975C2780653079 @default.
- W2569222975 hasConceptScore W2569222975C2780923524 @default.
- W2569222975 hasConceptScore W2569222975C2911091166 @default.
- W2569222975 hasConceptScore W2569222975C71924100 @default.
- W2569222975 hasConceptScore W2569222975C90924648 @default.
- W2569222975 hasLocation W25692229751 @default.
- W2569222975 hasOpenAccess W2569222975 @default.
- W2569222975 hasPrimaryLocation W25692229751 @default.
- W2569222975 hasRelatedWork W1125881793 @default.
- W2569222975 hasRelatedWork W2096047333 @default.
- W2569222975 hasRelatedWork W2205958192 @default.
- W2569222975 hasRelatedWork W2280795169 @default.
- W2569222975 hasRelatedWork W2502145464 @default.
- W2569222975 hasRelatedWork W2510588563 @default.
- W2569222975 hasRelatedWork W2519729984 @default.
- W2569222975 hasRelatedWork W2522251572 @default.
- W2569222975 hasRelatedWork W2555102075 @default.
- W2569222975 hasRelatedWork W2564404622 @default.
- W2569222975 hasRelatedWork W2566075579 @default.
- W2569222975 hasRelatedWork W2734666624 @default.
- W2569222975 hasRelatedWork W2745909886 @default.
- W2569222975 hasRelatedWork W2911460658 @default.